Selected article for: "display license and large number"

Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
  • Document date: 2020_3_24
  • ID: 6g34qwer_39
    Snippet: Lymphopenia was common in patients with COVID-19 and SARS patients, and can be used as an indicator of disease severity and prognosis. 23 75.4% patients with COVID-19 reported lymphopenia. 24 Due to the absence of ACE2 in lymphocyte, it has been proposed that the lymphocytopenia in SARS patient is caused by the indirect mechanism, including inflammation storm, vascular cell adhesion, soluble Fas ligand, and glucocorticoids. 12, 25 However, the SA.....
    Document: Lymphopenia was common in patients with COVID-19 and SARS patients, and can be used as an indicator of disease severity and prognosis. 23 75.4% patients with COVID-19 reported lymphopenia. 24 Due to the absence of ACE2 in lymphocyte, it has been proposed that the lymphocytopenia in SARS patient is caused by the indirect mechanism, including inflammation storm, vascular cell adhesion, soluble Fas ligand, and glucocorticoids. 12, 25 However, the SARS-CoV particles and genomic sequence were detected in a large number of circulating lymphocytes, causing destruction of lymphocytes. 26 In this trial, lymphocyte count in meplazumab-treated patients were restored in short time. CD147 is high expressed on the activated T cells, 17 which may All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cell adhesion and Fas ligand: 1, 2
    • cell adhesion and inflammation storm: 1, 2
    • cell adhesion and large number: 1, 2, 3, 4, 5, 6
    • cell adhesion and lymphocyte count: 1
    • disease severity and Fas ligand: 1
    • disease severity and genomic sequence: 1, 2
    • disease severity and indirect mechanism: 1
    • disease severity and inflammation storm: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • disease severity and large number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease severity and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease severity and lymphopenia report: 1
    • Fas ligand and lymphocyte count: 1
    • genomic sequence and large number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • inflammation storm and large number: 1
    • inflammation storm and lymphocyte count: 1, 2, 3
    • large number and lymphocyte count: 1, 2, 3, 4, 5